1. FRI0103 One-year follow-up of a nationwide cohort of patients with inflammatory arthritis, who switched from originator to biosimilar etanercept, focusing on patients who switched back to originator. an observational danbio study. (12th June 2018) Authors: Glintborg, B.; Sørensen, I.J.; Omerovic, E.; Mehnert, F.; Manilo, N.; Danebod, K.; Jensen, D.V.; Nordin, H.; Loft, A.G.; Hendricks, O.; Chrysidis, S.; Andersen, B.L.; Raun, J.L.; Lindegaard, H.; Espesen, J.; Jakobsen, S.H.; Hansen, I.M.J.; Dalsgaard, E.B.; Pedersen, D.D.; Kristensen, S. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 595 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. THU0189 One-year treatment retention after a nationwide non-medical switch from originator to biosimilar etanercept in 2, 061 patients with inflammatory arthritis followed in the danbio registry. (12th June 2018) Authors: Glintborg, B.; Sørensen, I.J.; Omerovic, E.; Mehnert, F.; Manilo, N.; Danebod, K.; Jensen, D.V.; Nordin, H.; Loft, A.G.; Hendricks, O.; Chrysidis, S.; Andersen, B.L.; Raun, J.L.; Lindegaard, H.; Espesen, J.; Jakobsen, S.H.; Hansen, I.M.J.; Dalsgaard, E.B.; Pedersen, D.D.; Kristensen, S. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 313 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗